ArticleAIDS and behavior2026
Implementation Journey with CAB LA for PrEP Among Men Who Have Sex with Men and Transgender Men: Insights from the PILLAR Trial Through 12 Months.
Article in AIDS and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05374525 (A Phase 4, Randomized, Open-label, Two-arm Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-volume Pre-exposure Prophylaxis), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 4, Randomized, Open-label, Two-arm Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-volume Pre-exposure Prophylaxis (PrEP) Sites in the U.S. for HIV Uninfected MSM and Transgender Men ≥ 18
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Men who have sex with men (MSM) and transgender men (TGM) account for an estimated 67% and < 1% of new HIV diagnoses in the United States, respectively. Long-acting cabotegravir (CAB LA), administered every 2 months, is the first LA medication approved for HIV-1 prevention. We present MSM and TGM experiences from CAB LA initiation through Month (M) 12 in the Phase 4 PILLAR trial (NCT05374525). Participants completed feasibility, acceptability, stigma, and perception questionnaires and semi-structured interviews at baseline, M6, and M12. Questionnaires were analyzed descriptively, and interviews were analyzed using a framework analysis approach. Clinical outcomes included HIV acquisition and persistence. During June 2022-August 2024, 201 participants enrolled; 6% were TGM, 23% Black or African American, 39% Hispanic/Latino, and 78% had taken oral PrEP in the last 6 months. Key reasons for choosing/switching to CAB LA were convenience, reduced adherence burden, and less worry about HIV. Most participants (92%) "always"/ "often" returned to usual activities immediately following injection. Persistence was 85% at M6 and 73% at M12, with no HIV acquisitions. At baseline, 15-29% of participants reported experiencing stigma and anxiety with oral PrEP versus 0-2% with CAB LA at M6 and M12. Participants reported greater engagement with sexual health and stronger patient-provider relationships. Feasibility and acceptability were high at M12 (mean scores of 4.4/5 and 4.6/5, respectively). Overall, CAB LA was perceived as highly feasible and acceptable, with high persistence and no HIV acquisitions, underscoring its potential to improve prevention outcomes and patient experience among MSM and TGM.Trial registry ClinicalTrials.gov number: NCT05374525 (May 2022).
Indexed as
Identifiers
42437832What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.